Table 1 Baseline characteristics of the study participant according to ESAs randomization group during P1
C.E.R.A | Darbepoetin alfa | p-value | |
|---|---|---|---|
(n = 15) | (n = 15) | ||
Sex (male), N (%) | 8 (53.3%) | 9 (60%) | 0.71 |
Age, year (mean, SD) | 70.5 (9.7) | 69.3 (10.3) | 0.73 |
Dry weight, kg (mean, SD) | 66.8 (18.5) | 77.0 (16.1) | 0.12 |
Diabetic, % | 53 | 47 | 0.71 |
Hypertensive, % | 93 | 93 | 1.0 |
Dialysis duration, hours/week (mean, SD) | 11.5 (1) | 11.1 (1) | 0.34 |
Time on dialysis, years (mean, SD) | 3.1 (2.9) | 2.5 (1.9) | 0.46 |
Hemoglobin, g/dl (mean, SD) | 10.9 (1.3) | 11.3 (1.1) | 0.37 |
Reticulocyte count, cells/μl (mean, SD) | 34147 (12823) | 38711 (20368) | 0.47 |
Ferritin, μg/l (mean, SD) | 357.4 (213.5) | 361.8 (127.3) | 0.95 |
Iron dose, mg/month (mean, SD) | 173.3 (103.3) | 186.7 (51.6) | 0.66 |
ESA dose, μg/month (median, IQR) | 120 (75–158) | 100 (64–146) | 0.32 |